TBAJ-876

Class: Diarylquinoline

Details of activity:	Anti-mycobacterial drug. Effective against Mycobacterium abscessus and Mycobacterium tuberculosis
Institute where first reported:	TB Alliance
Year first mentioned:	2019
Highest developmental phase:	Phase 1

Chemical structure(s):
Canonical SMILES:	CN(C)CC[C@@](C1=CC(=NC(=C1)OC)OC)([C@H](C2=C(C(=NC(=C2)OC)OC)OC)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
Isomeric SMILES:	CN(C)CC[C@@](C1=CC(=NC(=C1)OC)OC)([C@H](C2=CC(=NC(=C2OC)OC)OC)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
InChI:	InChI=1S/C31H37BrN4O7/c1-36(2)12-11-31(37,19-15-24(38-3)34-25(16-19)39-4)27(21-17-26(40-5)35-30(43-8)28(21)41-6)22-14-18-13-20(32)9-10-23(18)33-29(22)42-7/h9-10,13-17,27,37H,11-12H2,1-8H3/t27-,31-/m1/s1
InChI Key:	HHDDKDPLFXIPBX-DLFZDVPBSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/155510360

External links:
Guide to Pharmacology:	TBAJ-876
Main Source:	https://aac.asm.org/content/64/4/e02404-19
Citation:	https://aac.asm.org/content/64/2/e01540-19